BUSINESS OF CANNABIS: NEW YORK – ONE MONTH TO GO
Prohibition Partners and Business of Cannabis bring together the industry at a pivotal moment, for a day-long programme of top-level talks, discussions and networking, with the aim of developing a realistic roadmap for the sector in New York to reach its undoubted potential.
The event will provide a best-in-class networking experience and knowledge hub for the cannabis industry. Hear from the most influential thought leaders in business, finance and politics at iconic New York venue The Rainbow Room on 29 September. Be sure to join us for this first live event since the global pandemic by securing your seat.
TEXAN JUDGE OVERTURNS SMOKABLES BAN FINDING IT VIOLATES STATE CONSTITUTION
SWISS FEDERAL COUNCIL TO ALLOW DOCTORS TO PRESCRIBE MEDICAL CANNABIS WITHOUT AUTHORISATION
- Germany’s upcoming federal election prompts calls to loosen regulations on cannabis possession.
- The Brain Tumour Charity begins its first funding round for study on cannabis for glioblastoma brain tumours.
- Neuraxpharm and Panaxia Labs expand their strategic collaboration into Poland, after France and Germany.
- French medical cannabis pilot programme commences, allowing 3,000 patients to access medical cannabis for six months.
- President of Maltese cannabis company Releaf calls for cannabis reform after 136kg cannabis haul.
- Bill allowing free medical cannabis treatment in Niterói, Portugal, passes first discussion.
- Italian study finds oral CBD sprays are associated with improvements in patients with refractory migraines.
- California reports collecting US$817 million in taxes from adult-use cannabis sales this year, 55% more than in 2020.
- New Mexico to begin accepting cannabis producer licence applications in the lead-up to opening the adult-use market.
- North Carolina’s medical cannabis bill passes through several committees with backing from conservatives.
- New Jersey sets regulations for the adult-use cannabis market, though self-cultivation will remain illegal.
- The Wyoming Attorney General’s Office approves wording for two cannabis petitions.
- Jushi completes acquisition of cannabis processor Franklin Bioscience, adding an 8,000 sq. ft facility to its portfolio.
- Cannabis Council begins campaign ahead of general election to consolidate parties’ commitment to cannabis.
- Flora Growth closes deal with Hoshi International Inc., becoming its preferred supplier to the European market.
- Her Highness NYC partners with Ayurcann to bring its THC products to the Canadian market.
- Phyto Extraction to increase product range after submitting a licence amendment to include dried cannabis.
- Nextleaf receives another cannabis patent from the US Patent and Trademark Office, totalling over 80 patents so far.
- HEXO raises US$140 million after selling company shares to bolster its US expansion.
LATAM & CARIBBEAN
- Argentina looks into cannabis production and manufacturing legislation, citing its economic potential.
- APAC creates network for medical professionals prescribing medical cannabis.
- Khiron reports a 47% increase in medical cannabis revenue, bolstered by its Colombian and German regions.
- President of the National Seed Institute in Argentina signs regulations allowing direct registration of cannabis germplasm.
- Costa Rica looks into cannabis and hemp legislation after months of delays.
- Colombian project to regulate adult-use cannabis approved in its first debate in the House of Representatives.
- Brazil becomes of major interest to cannabis firms as it edges closer to regulating cannabis production.
- Cannabis company Cannava to become Argentina’s sole producer medical cannabis oil.
- Cannabis clinic chain Q² begins virtual operations in Mexico, investing US$1 million to expand into Latin America.
THE CANNABIS EXTRACTION REPORT
The cannabis extraction industry is growing and diversifying at a rapid pace to keep up with the constantly evolving government regulations and consumer demand across the globe. The Cannabis Extraction Report highlights how the extracts market is being driven by second-generation cannabis products in the adult-use markets, a shift away from flower in the medical markets and the booming global CBD industry.
Taking an in-depth look at the North American and European markets, and the regulations that currently govern extraction in these geographies, the report elaborates on how the shift towards extract-based products heralds the arrival of major pharmaceutical and FMCG companies, whilst offering significant commercial opportunities.
- The Japanese Ministry of Health to notify prefectures to ease cannabis restrictions on growers in September.
- The Thai government plans to turn 4,000 acres of land into a cannabis and hemp plantation for economic export.
- RA New Zealand pharmacist urges colleagues to learn more about cannabis medicine, to meet patient demand.
- The Australian government grants MediPharm labs AU$330,000 as part of its Manufacturing Modernisation Fund.
- Valens signs a distribution agreement, providing the company with access to the Japanese market.
- Therapeutic Goods Administration reports Queensland consumes 51.7% of medical cannabis in Australia.
- BOD Australia stocks up 12% after it records revenue of AU$7.5 million in 2021 financial year.
- Fijian government states it will be expanding hemp legislation in order to subsidise its tourism-based economy.
- New Zealand to bring in new quality requirements for medical cannabis products imported and sold in the country.
- Incannex registers with US regulators in preparation for its NASDAQ listing.
AFRICA & MIDDLE EAST
- The South African government unveils a US$1.9 billion strategy to industrialise and commercialise the cannabis industry.
- SAPHRA approves Canadian company TGOD’s extracts and flowers, completing its first shipment to South Africa.
- DRAPALIN commences supplying German pharmacies with medical cannabis from Lesotho.
- Israeli Ministry of Health records 100,000 medical cannabis patients in Israel this August.
- Quattro-Canna buys exclusive rights to whole plant processing equipment, leveraging the entire value chain.
- Basalt Pharma CEO Meir Ariel demands an expansion to list of qualifying illnesses for medical cannabis patients.